You are here: Industry Insights > Intercept

News List

Intercept reports additional positive data for Ocaliva in late-stage NASH trial firstwordpharma
April 12, 2019
Intercept reports additional positive data for Ocaliva in late-stage NASH trial.
Intercept sputters as it reveals full Ocaliva NASH data to doctors biopharmadive
April 12, 2019
Intercept is in the enviable position of leading in a heated competition to get the first NASH treatment to the market.
Intercept (ICPT) extends strategic partnership with TARGET Pharma Solutions biospectrumasia
October 17, 2017
TARGET-NASH is led by an academic steering committee chaired by Drs. Arun Sanyal, MD (Virginia Commonwealth University); Ken Cusi, MD (University of Florida), and Brent Tetri (St. Louis University).
FDA warning on Intercept’s Ocaliva after patient deaths pharmatimes
September 25, 2017
US regulators have issued a safety communication warning of the risk for serious liver injury and death from incorrect dosing of Intercept Pharmaceuticals' Ocaliva in patients with primary biliary cholangitis.
3 UK wins in Practice to Policy Health Awards pharmatimes
September 08, 2017
Intercept has announced the winners of its 2017 Practice to Policy Health Awards Programme in Europe and Canada.
NICE approves Intercept’s Ocaliva for use by UK's NHS pharmaceutical-technology
March 07, 2017
The National Institute for Health and Care Excellence (NICE) in the UK has approved Intercept Pharmaceuticals’ Ocaliva (obeticholic acid) for routine use by the National Health Service (NHS) in England, Wales and Northern Ireland.